Human adenovirus species B knob proteins as immunogens for inducing cross-neutralizing antibody responses
mSphere · 2025
DOI: 10.1128/msphere.00644-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift mSphere, 2025. Verfasst von Zhenwei Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Adenoviruses, Human, Antibodies, Neutralizing, Antibodies, Viral, Capsid Proteins. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST | National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Science and Technology Project of Guangzhou City.
Abstract (Originalsprache)
The re-emerging human adenovirus (HAdV) types 3, 7, 14, and 55 of species B have caused severe or even fatal acute respiratory disease. Therefore, the development of multivalent vaccines against HAdV types 3, 7, 14, and 55 remains an important goal. In our previous study, we identified a cross-neutralizing epitope that induced broadly reactive monoclonal neutralizing antibodies against the knob proteins of HAdV types 7, 11, 14, and 55. To study the immunogenicity of HAdV species B knob proteins, we evaluated humoral immune responses to the knob proteins in vivo and in vitro . We found that the knob proteins elicited robust binding and neutralizing antibody responses after three immunizations of mice. In addition, mouse antisera raised against the knob proteins exhibited cross-neutralizing activity against original species B members. Furthermore, immunization with a mix of HAdV-3, 7, and 55 knob proteins protected Chinese tree shrews against an experimental HAdV challenge. Our results provide insight into the immunogenicity of HAdV species B knob proteins. IMPORTANCE Human adenovirus (HAdV) species B are common pathogens causing severe pneumonia in children, and there is currently no vaccine available. Because there are many HAdV species B types, developing broad-spectrum vaccines against HAdV species B is an important research goal. Our study revealed that immunization with recombinant HAdV species B knob proteins effectively elicited cross-neutralizing antibody responses against original species B members with protective immunity. This study provides a novel insight into the immunogenicity of HAdV species B knob proteins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou…
- Guangdong Xinmai Biotechnology Co., Ltd, Guangzhou, China.
- Deep Evolution (Guangzhou) Biotechnology Co., Ltd, Guangzhou, China.
ORCID-Profile: Zhenwei Liu, Rong Zhou, Dehui Chen, Xingui Tian
Förderung
- MOST | National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Science and Technology Project of Guangzhou City
Zitieren
APA
Liu, Z., Xian, Y., Lan, J., Zhou, Z., Li, X., Zhou, R., Chen, D., & Tian, X. (2025). Human adenovirus species B knob proteins as immunogens for inducing cross-neutralizing antibody responses. mSphere. https://doi.org/10.1128/msphere.00644-24
Vancouver
Liu Z, Xian Y, Lan J, Zhou Z, Li X, Zhou R, et al. Human adenovirus species B knob proteins as immunogens for inducing cross-neutralizing antibody responses. mSphere. 2025. doi:10.1128/msphere.00644-24
BibTeX
@article{Liu2025,
author = {Liu, Zhenwei and Xian, Yuting and Lan, Jixian and Zhou, Zhichao and Li, Xiao and Zhou, Rong and Chen, Dehui and Tian, Xingui},
title = {Human adenovirus species B knob proteins as immunogens for inducing cross-neutralizing antibody responses},
journal = {mSphere},
year = {2025},
doi = {10.1128/msphere.00644-24}
}
EUVIMED